- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.05. | Intensity Therapeutics GAAP EPS of -$0.96 | 1 | Seeking Alpha | ||
| INTENSITY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 07.05. | Intensity Therapeutics Inc.: Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | 537 | PR Newswire | Cash and cash equivalents of $10.2 million as of March 31, 2026
Favorable efficacy and safety reported in a small sample of triple negative breast cancer ("TNBC")... ► Artikel lesen | |
| 01.05. | Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now | 1 | Zacks | ||
| 27.03. | Intensity Therapeutics Inc.: Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update | 210 | PR Newswire | Raised over $20 million in gross proceeds in 2025 and held $11.9 million in cash and cash equivalents as of December 31, 2025, with a cash runway into the second... ► Artikel lesen | |
| 27.03. | Intensity Therapeutics GAAP EPS of -$8.56 misses by $0.69 | 3 | Seeking Alpha | ||
| 27.03. | INTENSITY THERAPEUTICS, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| 24.03. | Intensity Therapeutics erhält neues US-Patent für Krebstherapie | 3 | Investing.com Deutsch | ||
| 23.03. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.03. | Intensity Therapeutics Updates Breast Cancer Trial, Files To Resume Enrollment Following Study Pause | 3 | Benzinga.com | ||
| 12.03. | Intensity Therapeutics Inc.: Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study | 271 | PR Newswire | Preliminary observations of the INVINCIBLE-4 Study to date showed that five (5) out of seven (7) patients (71.4%) who received INT230-6 prior to standard of care... ► Artikel lesen | |
| 12.03. | Intensity Therapeutics reports early trial data in breast cancer | 1 | Investing.com | ||
| 06.03. | Intensity Therapeutics erfüllt wieder NASDAQ-Anforderungen | 10 | Investing.com Deutsch | ||
| 06.03. | Intensity Therapeutics regains Nasdaq compliance | 1 | Investing.com | ||
| 06.03. | Intensity Therapeutics regains compliance with Nasdaq's minimum bid price requirement | 2 | Seeking Alpha | ||
| 06.03. | Intensity Therapeutics Inc.: Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement | 224 | PR Newswire | SHELTON, Conn., March 6, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company... ► Artikel lesen | |
| 05.03. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 5 | SEC Filings | ||
| 13.02. | Intensity Therapeutics announces 1-for-25 reverse stock split | 21 | Investing.com | ||
| 13.02. | Intensity Therapeutics kündigt Aktienzusammenlegung im Verhältnis 1:25 an | 4 | Investing.com Deutsch | ||
| 13.02. | Intensity Therapeutics Inc.: Intensity Therapeutics Announces Reverse Stock Split | 323 | PR Newswire | Intensity's common stock is expected to begin trading on a post-split adjusted basis on February 19, 2026
SHELTON, Conn., Feb. 13, 2026 /PRNewswire/ -- Intensity... ► Artikel lesen | |
| 23.01. | INTENSITY THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 77,05 | -1,34 % | BioNTech und BMS melden neue Daten für Lungenkrebskandidat Pumitamig | BioNTech SE und Bristol Myers Squibb haben auf dem ASCO-Jahreskongress in Chicago erste globale Phase-2-Daten für den bispezifischen Immunmodulator Pumitamig in Kombination mit Chemotherapie bei fortgeschrittenem... ► Artikel lesen | |
| NOVAVAX | 8,080 | -1,70 % | NOVAVAX INC: Stabilität vor der nächsten Bewegung | ||
| CRISPR THERAPEUTICS | 44,705 | -0,60 % | CRISPR Therapeutics AG (CRSP): One of The most Shorted Mid Cap Stocks to Buy on Robust Gene Editing Pipeline | ||
| EDITAS MEDICINE | 2,340 | -0,43 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,904 | -2,90 % | Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab | Ginkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity business
BOSTON, May 7, 2026 /PRNewswire/ -- Ginkgo... ► Artikel lesen | |
| NOVOCURE | 15,175 | +11,05 % | NovoCure Ltd - 8-K, Current Report | ||
| PRAXIS PRECISION MEDICINES | 254,00 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 35,590 | 0,00 % | Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for... ► Artikel lesen | |
| JADE BIOSCIENCES | 16,940 | 0,00 % | Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy | ~70% IgA reductions sustained at 12 weeks after a single dose of JADE101>70% IgA reductions projected at steady state with a single subcutaneous maintenance injection every 12 weeksIgA-lowering effect... ► Artikel lesen | |
| QIAGEN | 31,920 | -2,18 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Qiagen mit einem Kursziel von 43 US-Dollar auf "Buy" belassen. Das Feedback aus Gesprächen mit etlichen US-Laborexperten deute darauf hin, dass... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 86,86 | -0,07 % | Weekly Buzz: AstraZeneca, JNJ Get FDA Nod; Eli Lilly To Acquire Curevo; APGE Advances Zumilokibart | NEW BRUNSWICK (dpa-AFX) - This week in the biotech space, there were regulatory approvals across the U.S. and Europe, collaborations, acquisitions, and positive data readouts spanning multiple... ► Artikel lesen | |
| ADMA BIOLOGICS | 7,970 | 0,00 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
| SUMMIT THERAPEUTICS | 14,755 | -0,10 % | All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy | ||
| ERASCA | 11,970 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,315 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen |
INTENSITY THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 3,770 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INTENSITY THERAPEUTICS INC finden Sie auf Wallstreet Online.